It is widely known that pre-training systemic administration of the muscarinic antagonist scopolamine (SCP) (0.5 mg/kg, i.p.) leads to anterograde memory impairment in retention tests. The administration of the a 7 -nicotinic receptor agonist choline (Ch) in the dorsal hippocampus (0.8 lg/hippocampus) immediately after memory reactivation allowed recovery from scopolamine-induced memory impairment. This effect of Ch was time-dependent, and retention performance was not affected in drug-treated mice that were not subjected to memory reactivation, suggesting that the performance effects are not due to non-specific effects of the drug. The effects of Ch also depended on the age of the reactivated memory. Altogether, our results suggest that Ch exerts its effects by modulating memory reconsolidation, and that the memory impairment induced by low doses of SCP is a memory expression failure and not a storage deficit. Therefore, reconsolidation, among other functions, might serve to change memory expression in later tests. Summarizing, our results open new avenues about the behavioral significance and the physiological functions of memory reconsolidation, providing new strategies for recovering memories from some types of amnesia.
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Introduction
Memory consolidation regards the underlying processes occurring after a learning situation where memory is stabilized and strengthened. New memories are labile and sensitive to ''disruption'' before undergoing a series of processes that render the memory representation progressively stable (McGaugh, 1966 (McGaugh, , 2000 Roozendaal & McGaugh, 2011) . Memory consolidation depends on modulation by neurotransmitter systems (McGaugh, 2000; Roozendaal & McGaugh, 2011) . Among them, central cholinergic system has been implicated in learning and memory processes, either in invertebrates (Berón de Astrada & Maldonado, 1999; Terazima & Yoshino, 2010; Weinberger, 2006) Cholinergic blockade by scopolamine (SCP, a muscarinic cholinergic receptor antagonist) before training cause anterograde memory impairment (Berón de Astrada & Maldonado, 1999; Blake et al., 2011; Decker & McGaugh, 1989; Decker, Tran, & McGaugh, 1990; Ohno & Watanabe, 1996; Rush, 1988) . This scopolamine-induced memory impairment was also found in human subjects (Frumin, Herekar, & Jarvik, 1976; Ghoneim & Mewaldt, 1975 , 1977 Richardson et al., 1985) .
Several studies have shown recovery from memory impairment, suggesting that a hidden memory can be expressed under the appropriate conditions (Cahill, McGaugh, & Weinberger, 2001; Gold, Haycock, Marri, & McGaugh, 1973; Haycock, Gold, Macri, & McGaugh, 1973; Nader & Wang, 2006; Parvez, Stewart, Sangha, & Lukowiak, 2005; Philips, Tzvetkova, Marinesco, & Carew, 2006; Rescorla, 1988) . Recovery from amnesia lead us to consider alternative mechanisms for the amnesic treatments, different from impairment of information encoding, i.e. memory expression deficit.
Post-reactivation administration of choline (Ch), a specific a7-nicotinic cholinergic receptor agonist (Albuquerque, Pereira, Alkongdon, & Rogers, 2009) modulates memory reconsolidation, either enhancing or impairing it, depending on training conditions (Boccia et al., 2010) . Ch impairs memory reconsolidation when mice are trained with a high footshock, but enhances it when animals are trained with a mild footshock (Boccia et al., 2010) .
